---
title: "ROSEN, LEADING INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236611369.md"
description: "Rosen Law Firm urges Geron Corporation investors who purchased securities between February 28, 2024, and February 25, 2025, to secure counsel before the May 12, 2025, lead plaintiff deadline for a class action lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit claims Geron made misleading statements about its drug RYTELO, affecting its financial prospects. Interested investors can contact Phillip Kim, Esq. for more information. No class has been certified yet, and investors can choose their counsel or remain absent from the class."
datetime: "2025-04-18T15:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236611369.md)
  - [en](https://longbridge.com/en/news/236611369.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236611369.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/236611369.md) | [繁體中文](https://longbridge.com/zh-HK/news/236611369.md)


# ROSEN, LEADING INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) —

**WHY:** Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important **May 12, 2025 lead plaintiff deadline.**

**SO WHAT:** If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

**WHAT TO DO NEXT:** To join the Geron class action, go to https://rosenlegal.com/submit-form/?case\_id=36747 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court **no later than May 12, 2025.** A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

**WHY ROSEN LAW:** We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

**DETAILS OF THE CASE:** According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) despite contrary representations to investors, a lack of awareness of RYTELO among health care providers, the weekly monitoring requirement, and seasonality and existing competition would impair Geron’s ability to capitalize on the purportedly significant unmet need for the drug; (2) accordingly, the RYTELO launch was unlikely to be as profitable as Geron had led investors to believe; (3) as a result, Geron’s business and/or financial prospects were overstated; and (4) as a result, Geron’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Geron class action, go to https://rosenlegal.com/submit-form/?case\_id=36747 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

case@rosenlegal.com

www.rosenlegal.com

### Related Stocks

- [Geron Corporation (GERN.US)](https://longbridge.com/en/quote/GERN.US.md)
- [NVE Corporation (NVEC.US)](https://longbridge.com/en/quote/NVEC.US.md)

## Related News & Research

- [Balancing Softer Near-Term Guidance with Capital Discipline and Pipeline Catalysts: Why Geron Merits a Buy Rating and $4 Target](https://longbridge.com/en/news/272348012.md)
- [Geron Extends $250 Million Loan Facility Terms With Pharmakon Funds](https://longbridge.com/en/news/271640786.md)
- [Warren Buffett Bet Big On Oil In Q4: Here's How Much Berkshire Hathaway Is Up On Chevron Stock In 2026](https://longbridge.com/en/news/281213097.md)
- [Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans](https://longbridge.com/en/news/267210226.md)
- [Geron Signs Loan Agreement Amendment With BioPharma Credit](https://longbridge.com/en/news/271642306.md)